欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的：考察奥沙利铂＋亚叶酸钙＋5-氟尿嘧啶（mFOLFOX6）、奥沙利铂＋卡培他滨（CapeOX）、伊立替康＋亚叶酸钙＋5-氟尿嘧啶（FOLFIRI）3种化疗方案在转移性结直肠癌治疗中的临床疗效,并进行成本-效果分析。方法：将48例结直肠癌患者按治疗方案分为mFOLFOX6组30例、CapeOX组8例和FOLFIRI组10例,观察3组患者的临床疗效、不良反应,并进行成本-效果分析。结果：mFOLFOX6组、CapeOX组和FOLFIRI组患者的临床有效率分别为96.67%、87.50%和80.00%,mFOLFOX6组明显高于其他两组,差异有统计学意义（P〈0.05）。mFOLFOX6组患者的胃肠道不良反应发生率高（70.00%）,FOLFIRI组患者的骨髓抑制发生率高（70.00%）;mFOLFOX6组和CapeOX组均有患者发生肝功能损伤,但差异无统计学意义（P〉0.05）。mFOLFOX6、CapeOX和FOLFIRI方案的成本-效果比分别为11 950、15 674、18 397,敏感度分析结果与其一致。结论：mFOLFOX6方案治疗转移性结直肠癌的成本-效果优于CapeOX和FOLFIRI方案,但其胃肠道不良反应发生率较高。
英文摘要：
OBJECTIVE： To investigate clinical efficacy of oxaliplatin＋calcium folinate＋5-fluorouracil （mFOLFOX6）, oxalipl- atin＋capecitabine（CapeOX）, irinotecan＋calcium folinate＋5-fluorouracil （FOLFIRI） for metastatic colorectal cancer, and to conduct cost-effectiveness analysis. METHODS： 48 patients with colorectal cancer were divided into mFOLFOX6 group （30 cases）, Cape- OX group （8 cases） and FOLFIRI group （10 cases）. Clinical efficacy and ADR of 3 groups were analyzed, and cost-effectiveness analysis was also conducted. RESULTS： Clinical effective rates of mFOLFOX6 group, CapeOX group and FOLFIRI group were 96.67%, 87.50% and 80.00%, respectively, the mFOLFX6 group was significantly higher than the other 2 groups, with statistical significance（P〈0.05）, mFOLFOX6 group had high incidence of gastrointestinal side effects （70.00%）. FOLFIRI group had high incidence of myelosuppression （70.00%）. CapeOX and mFOLFOX6 group suffered from liver injury possibly, without statistical significance （P〉0.05）. The C/E of mFOLFOX6 group, CapeOX group and FOLFIRI group were 11 950, 15 674 and 18 397 re- spectively, to which results of sensitivity analysis were same. CONCLUSIONS： The cost-effectiveness of mFOLFOX6 regimen is superior to CapeOX and FOLFIRI regimen in the treatment of metastatic colorectal cancer, but it has the high incidence of gastroin- testinal side effects.
同期刊论文项目
同项目期刊论文
期刊信息
位置：